Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$19.98 USD

19.98
1,470,373

-0.28 (-1.38%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $19.97 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PCRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Pacira BioSciences, Inc. [PCRX]

Reports for Purchase

Showing records 661 - 680 ( 722 total )

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 661

03/15/2013

Industry Report

Pages: 5

LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of March 18

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 662

03/07/2013

Company Report

Pages: 9

Q4 Financials As Expected; Raising FV to $32 on New Long-Term Sales Estimates and Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 663

03/04/2013

Industry Report

Pages: 32

Emerging Pharmaceuticals-March and Remaining 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 664

02/20/2013

Daily Note

Pages: 5

January Symphony Health Data for EXPAREL

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 665

02/15/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of February 17

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 666

01/23/2013

Daily Note

Pages: 5

December Symphony Health Data for EXPAREL

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 667

01/18/2013

Industry Report

Pages: 7

LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of January 20

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 668

01/17/2013

Company Report

Pages: 8

Preannounced Q4 EXPAREL Sales Beat Our Expectations;

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 669

12/28/2012

Industry Report

Pages: 6

LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of December 30.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 670

12/19/2012

Daily Note

Pages: 5

November Symphony Health Data for EXPAREL

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 671

12/07/2012

Industry Report

Pages: 5

LIFE SCIENCES

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 672

12/06/2012

Daily Note

Pages: 5

Partnership With Aratana Therapeutics for EXPAREL Animal Health Rights Provides Future Potential Upside With Little Risk, In Our View

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 673

11/21/2012

Daily Note

Pages: 5

October Symphony Health Data for EXPAREL. Reiterate OUTPERFORM and $23 Fair Value

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 674

11/16/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of November 18

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 675

11/13/2012

Daily Note

Pages: 5

New Phase 4 Data Supporting EXPAREL Use Via TAP Infiltration Opens New Avenue to Drive Physician Adoption

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 676

11/09/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of November

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 677

11/01/2012

Company Report

Pages: 8

Q3 EXPAREL Sales Meet Our Expectations As Launch Continues To Go Well. Reiterate OUTPERFORM and $23 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 678

10/24/2012

Daily Note

Pages: 5

September Symphony Health Data for EXPAREL; Reiterate OUTPERFORM and $23 Fair Value

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 679

10/18/2012

Daily Note

Pages: 5

Medical Community Recognizes Positive Outcomes With EXPAREL Use in Plastic Surgery; Reiterate OUTPERFORM and $23 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 680

10/08/2012

Daily Note

Pages: 5

Phase 4 Top-line Data Reinforces Health Economic Benefits of EXPAREL as Foundation for Multimodal Regimen

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party